Loading...
•
Mar 31, 2022
Bio-Techne Q3 2022 Earnings Report
Bio-Techne's third quarter results for fiscal year 2022 were released, showing revenue growth and strategic developments.
Key Takeaways
Bio-Techne reported a 19% increase in net sales, reaching $290.4 million, with organic growth of 17%. GAAP EPS was $1.48, and adjusted EPS was $2.14. The company highlighted strong performance in both Protein Sciences and Diagnostics and Genomics segments, and announced an exclusive agreement with Thermo Fisher Scientific.
Organic revenue increased by 17% to $290.4 million.
GAAP EPS was $1.48, and adjusted EPS reached a record $2.14.
Protein Sciences delivered organic growth of 16%, while Diagnostics and Genomics achieved 19% organic growth.
An exclusive agreement with Thermo Fisher Scientific to develop and commercialize the ExoTRU kidney transplant rejection test was announced.
Revenue by Segment
Forward Guidance
No specific forward guidance was provided in the release.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...